Pharmana

Pharmana Wider View Vol.2 – Cardiovascular Disease

Pharmana Wider View Vol.2 – Cardiovascular Disease 150 150 mana

PHARMANA WIDER VIEW - August 2019 Vol2 Cardiovascular disease (CVD), or heart disease, is an umbrella term that includes all conditions affecting the heart. By 2020, 50 percent of global health care expenditures – about $4 trillion – will be spent on three leading causes of death: cardiovascular diseases, cancer and respiratory diseases. According to…

Pharmaceutical Stock Market Analaytics

Pharmaceutical Stock Market Analaytics 1900 410 mana

Pharmaceutical Stock Market Analaytics Due to the lack of coherent information from Iranian pharmaceutical market and in order to meet this industry’s need, we play our role at Pharmana Group by collecting and categorizing available data of the stock exchange in the Iranian pharmaceutical industry, and revising the stock changes and the companies’ trend. So…

Iranian Pharmaceutical Market and Industry Analysis

Iranian Pharmaceutical Market and Industry Analysis 1900 410 mana

Iranian Pharmaceutical Market and Industry Analysis Due to Iran’s untapped health market and its capabilities (especially pharmaceutical market), improvement of environmental factors, recent international agreements, health transformation plan and governmental policies for supporting foreign investment serious actions have been taken by domestic and international players and investors to consider Iran’s Market. Lack of accumulation of…

Pharmana Wider View Vol.1 – Dementia

Pharmana Wider View Vol.1 – Dementia 150 150 ali

PHARMANA WIDER VIEW - July 2019 Vol1 The global Alzheimer’s drugs market is going to grow at a CAGR of 1.90% during the period 2017-2021 with Key vendors being Allergan, Eisai Pharmaceuticals, Johnson & Johnson, and Novartis, with other prominent vendors Amgen and Pfizer. Much of the increase will be in developing countries. Already 58%…

پشتیبانی مانا
چگونه می توانیم به شما کمک کنیم؟
گروه مشاوره مانا
راهکاری هوشمندانه